In August 2024，Phase IIl clinical results of Ebronucimab in Chinese patients with hypercholesterolemia were published at the 《Pharmacological Research》.
伊喜宁®
(Ebronucimab Injection,PCSK9 Monoclonal antibody)
伊喜宁® (Ebronucimab Injection) is an innovative PCSK9 monoclonal antibody independently developed by AD Pharmaceuticals, which is mainly used to treat primary hypercholesterolemia and mixed hyperlipidemia, including homozygous familial hypercholesterolemia (HoFH), heterogeneous familial hypercholesterolemia (HeFH) and hypercholesterolemia patients with atherosclerosis cardiovascular disease.Ebronucimab, AD Pharmaceuticals’ first drug approved by NMPA, is also Akeso’s first non-oncology drug.
On September 30, 2024, the National Medical Products Administration (NMPA) of China has approved the new drug application (NDA) of 伊喜宁® (Ebronucimab Injection, PCSK9) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH).
PCSK9 is the major regulator of low-density lipoprotein receptors (LDLR) level on the cell surface and can inhibit LDLR circulation pathway. By reducing the PCSK9 circulation level, Ebronucimab increases the expression of LDLR on the cell surface and increases the removal low-density lipoprotein cholesterol (LDL-C), thereby reducing the LDL-C level in the circulation. PCSK9 monoclonal antibody is known as the most effective lipid-lowering drug following the statin drugs. The marketed PCSK9 monoclonal antibody has demonstrated a significant reduction in cholesterol and a reduction in the incidence of heart attack or stroke in patients, based on the background treatment of statin drugs. Clinical trials have shown that Ebronucimab has a more complete inhibition of PCSK9 compared to the products with the same target, and can significantly reduce cholesterol in all patients. An authoritative institution forecasts that PCSK9 monoclonal antibody market in China will grow at a compound annual growth rate of 36.9% from 2023 to 2030.
The research subject of Ebronucimab, "Research and Development of New Anti-PCSK9 Monoclonal Antibody (AK102) for Cardiovascular Diseases", has been approved by Guangdong Province's R&D program of key fields (precision medicine and stem cells).
Adverse event feedback platform
Research and development process
-
2024In September 2024,NMPA approved the new drug application (NDA) of 伊喜宁® (Ebronucimab Injection, PCSK9) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH).
-
2023In June 2023，NMPA accepted Ebronucimab (PCSK9) marketing application in two indications：1) primary hypercholesterolemia and mixed hyperlipidemia； 2) heterozygous familial hypercholesterolemia (HeFH).In May 2023，Phase IIl clinical results of Ebronucimab were published at the European Atherosclerosis Society (EAS 2023).
-
2022In November 2022，the Phase II clinical results of Ebronucimab in the treatment of Hyperlipidemia were pulished in a poster session at AHA Scientific Sessions 2022.In November 2022，the rigistry Phase III clinical trial of Ebronucimab in the treatment of primary hypercholesterolemia patients reached its primary endpoint.In July 2022, the patient enrollment was completed in the registered clinical study of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.
-
2021In December 2021, patient enrollment was completed ahead of schedule for the key registered Phase III clinical trial of Ebronucimab in the treatment of primary hypercholesterolemia and mixed hyperlipidemia.In September 2021, the Phase II clinical study of Ebronucimab in the treatment of hypercholesterolemia patients at high risk or extremely high risk for cardiovascular disease reached its primary endpoint.
-
2020In December 2020, patient enrollment was completed ahead of schedule for the Phase IIb clinical trial of Ebronucimab in the treatment of high-risk/extremely high-risk hypercholesterolemia.
-
2019In May, the first patient was enrolled in the Phase II clinical trial of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.
-
2018In March 2018, Ebronucimab was first approved in China to initiate clinical trials for the treatment of hyperlipidemia.